Articles tagged with Myocarditis
The AIR-STEMI trial found that functional coronary angiography significantly reduced major cardiovascular events and complications by 38% and 37%, respectively, compared to conventional angiography. The study showed that this approach can improve current care for high-risk patient populations by selecting and treating only clinically i...
ICDs did not improve overall primary endpoint but showed benefit in younger patients (under 70) with a 72% reduction in sudden cardiac death. In contrast, older patients did not derive benefit from ICDs.
Dr. Sebastian Spethmann joins JMIR Cardio as Editor-in-Chief, bringing expertise in heart failure, cardiomyopathies, and digital health. He aims to integrate digital advancements into routine clinical care, enhancing cardiovascular health systems and patient outcomes.
Katherine Wilemon, Family Heart Foundation CEO, receives Honorary Fellow Award from ASPC for her advocacy and research efforts in inherited lipid disorders. The award reflects the organization's impact on advancing care and awareness for conditions like familial hypercholesterolemia.
A study found that early myocarditis onset after immune checkpoint inhibitor therapy significantly increases the risk of death from treatment-related causes. Patients who developed co-occurring myositis and myasthenia gravis were also at a higher risk, with some cases leading to fatal outcomes.
A new study found that older people who forego necessary dental procedures due to financial barriers may experience heart failure, a heart attack, a stroke, or dementia. The researchers suggest that alleviating upstream factors such as financial constraints could prevent chronic disease.
A study by Florida Atlantic University found that ultra-processed foods (UPFs) are associated with a 47% higher risk of cardiovascular disease. Researchers analyzed data from the US National Health and Nutrition Examination Survey and found that those consuming high amounts of UPFs had a significant increase in heart attack and stroke ...
Researchers have uncovered a new understanding of how cardiac events are interconnected with the brain and nervous/immune systems. They found that sensory neurons in the vagus nerve detect injury and transfer signals to dedicated brain structures, leading to activation of the immune system.
Researchers identified CXCL10 and IFN-gamma as the major drivers of myocarditis in mRNA-vaccine recipients. The two proteins trigger an inflammatory response that damages heart muscle cells, leading to hospitalizations and deaths in severe cases. Most cases recover swiftly with full heart function retained.
A new study found that scar tissue in the heart of healthy male endurance athletes aged 50 or older may increase their risk of abnormal heart rhythms and sudden cardiac death. The research used magnetic resonance imaging and ECG recorders to track the participants' heart activity over two years.
A study published in Nature Cardiovascular Research identified distinct immune signatures in myocarditis caused by SARS-CoV-2 infection and mRNA vaccines compared to non-COVID-19 myocarditis. The findings suggest a stronger immune response in post-COVID-19 myocarditis, while the inflammation appeared milder in post-vaccination cases.
A cohort study found no increase in sudden cardiac arrest/sudden cardiac death among young competitive athletes in the US, contradicting reports that linked COVID-19 infection and vaccination to the risk. The study suggests that many athlete cases shown in social media videos occurred before the pandemic, not due to COVID-19.
Researchers document five cases of parvovirus B19-induced myocarditis in preschoolers from northern Greece, highlighting the virus's unique impact on endothelial cells. The study emphasizes the importance of quick diagnosis and treatment to reduce mortality and morbidity in children.
Researchers at UVA discovered the heart reacts to viral infections in one of three ways, with specific gene patterns indicating healing or damage. This finding may lead to better treatments for people at risk of heart failure and other chronic conditions linked to viral infections.
Researchers have identified changes in immune and stromal cells that underlie myocarditis, a rare but deadly complication of cancer immunotherapy. The study suggests that targeted treatments might be able to address myocarditis while allowing patients to continue receiving life-saving anti-tumor immunotherapy.
Patients with post-COVID-19 mRNA vaccination myocarditis show lower cardiovascular complications at 18 months compared to those with conventional myocarditis. However, affected patients may require medical management for several months after hospital discharge.
This review article sheds light on histopathologic characteristics of ICI-induced myocarditis, highlighting the role of macrophages in diagnosis. Quantifying CD68+ macrophage abundance may enhance diagnostic sensitivity, providing valuable insights into clinical outcomes.
A new case report presents OPM-MCG as a potential method for therapy monitoring in fulminant myocarditis. The study reveals that OPM-MCG can detect substantial myocardial injury and monitor therapy response, aligning with cardiac magnetic resonance findings.
Researchers used OPM-MCG to monitor a patient with fulminant myocarditis, revealing abnormalities characteristic of substantial myocardial injury. The test normalized after therapy, aligning with findings from cardiac magnetic resonance imaging.
A cohort study found statistical signals for myocarditis and pericarditis after BNT162b2 vaccination in children aged 12-17 years, consistent with previous reports. Seizures after mRNA-1273 vaccinations in younger age groups require a robust epidemiologic investigation to confirm findings.
Researchers found that viral infections like adenovirus create conditions for arrhythmias by disrupting gap junctions and ion channels in the heart. This discovery opens new directions to diagnose and treat viral infections affecting the heart, particularly for individuals with acute infections.
Recent studies have found no link between COVID-19 vaccination and sudden cardiac arrest in athletes. However, a small decrease in VO2 Max has been observed after vaccination, which may be temporary and have minimal clinical relevance.
A study published in Science reveals that ganglia in the neck region are responsible for disrupting melatonin production and causing sleep disturbances in people with heart conditions. Researchers found that macrophages accumulate in the ganglion, leading to inflammation and scarring, which can be treated with drugs.
A recent study published in JAMA Pediatrics monitored the safety of Pfizer-BioNTech COVID-19 vaccine in over 3 million children, identifying only rare cases of myocarditis or pericarditis, consistent with previous reports. The results provide additional evidence supporting the safety of COVID-19 vaccines in children ages 5 to 17.
A small number of patients with acute myocarditis after COVID-19 vaccination showed signs of heart muscle inflammation, while asymptomatic patients had normal cardiac tissue. The study suggests that symptoms alone are a poor indicator of myocardial injury after vaccination.
A study of 1.65 million BNT162b2 vaccinations among Ontario adolescents found a rare but significant risk of myocarditis or pericarditis. The researchers emphasize that while the events are uncommon, they should be weighed against the benefits of COVID-19 vaccination.
A study by Mass General Brigham found elevated levels of spike protein, increased cytokines, and troponin in the blood of 16 adolescents and young adults who developed myocarditis after COVID mRNA vaccination. The researchers also discovered no differences in antibody production or auto-antibodies between cases and controls.
A multicenter study found that COVID-19 vaccination following multisystem inflammatory syndrome (MIS-C) is safe, with mild reactions and no serious complications. The study included 385 patients aged 5 years or older, all of whom received at least one vaccine dose without any reports of myocarditis or MIS-C reoccurrence.
Researchers at Michigan Medicine have developed a new biomarker-based strategy to screen for immune checkpoint inhibitor-induced myocarditis, which can cause muscle damage and liver injury. Early detection of these biomarkers can lead to earlier treatment and improved survival rates.
A case of a 14-year-old girl who had a cardiac arrest at an overnight camp emphasizes the need for preparation and training for rare but often fatal events. The survival of the patient is attributed to the quick response of emergency medical services and bystander CPR.
A large study found that mRNA vaccines increased myocarditis risk in younger males, especially after the second dose. Absolute rates were low, with higher observed rates compared to expected rates.
Researchers identified specific immune cells driving deadly heart inflammation in cancer immunotherapy patients, and found that CD8 T cells target the heart muscle. The study's findings have led to investigations into preventing or treating this form of myocarditis, a common but fatal side effect of ICIs.
Researchers from Vanderbilt University Medical Center have identified the cardiac antigen α-myosin as the mechanism for immunotherapy-related myocarditis, a rare but deadly complication affecting less than 1% of patients. The discovery sets the framework to identify biomarkers and develop strategies to tolerate immunotherapy in at-risk...
A study found that males younger than 40 years old who received the Moderna COVID-19 vaccine had the highest rates of myocarditis, but overall cases are rare. The study suggests that choosing specific vaccines for certain populations may maximize benefits and minimize adverse events.
A UCSF-led study sheds light on the mechanisms behind sex differences in ICI-induced myocarditis, a potentially fatal side effect of cancer immunotherapy. The research suggests that immune checkpoint inhibitors may interact with sex hormones to cause cardiac toxicity in female patients.
A new preclinical study discovered the underlying cause of gender differences in immunotherapy-associated myocarditis and identified potential treatment strategies. Hormone therapies targeting the endocrine-cardiac-immune pathway may reduce this risk without affecting treatment efficacy.
A comprehensive review and meta-analysis found that young adults under 40 have a slightly elevated risk for myocarditis or pericarditis after mRNA COVID-19 vaccination. The analysis analyzed data from over 58 million participants and explored the relationship between COVID-19 vaccine and these rare but dangerous adverse reactions.
A recent study by Penn State College of Medicine scientists found that the risk of developing myocarditis — inflammation of the heart muscle — is seven times higher with COVID-19 infection than with COVID-19 vaccination. Patients with myocarditis can experience chest pains, shortness of breath or an irregular heartbeat.
A new Israeli study found that myocarditis cases were rare and mild after the third dose of Pfizer-BioNTech COVID-19 vaccine, with a risk of 1 in 15,000 among young males. The study's findings suggest potential explanations for the increased risk, including medical precautions and time between doses.
A new study from the National Institutes of Health RECOVER initiative found that post-acute COVID-19 in children is less common than in adults, but more frequent than hospitalization rates for acute COVID-19. Children with medical complexity and those younger than five years old are at higher risk of long COVID-19.
A case-control study found that pregnant women with higher folate levels are at a lower risk of having children with congenital heart disease. The researchers measured red blood cell folate levels and found that those with CHD had significantly lower median levels than those without CHD.
A recent study found that COVID-19 infection significantly increases the risk of myocarditis compared to vaccination, with a 11-fold higher risk in unvaccinated individuals. The study analyzed nearly 43 million people in England and found that COVID-19 vaccine-associated myocarditis is rare.
A recent study published by The BMJ confirms previous reports that myocarditis is rare but cases are highest among young males shortly after a second dose of mRNA vaccine, especially Moderna. The risk of myocarditis or pericarditis might be lower when the second dose is given more than 30 days after the first dose.
A new study from Mount Sinai Heart found that heart failure patients unvaccinated against COVID-19 are three times more likely to die from it than those who are fully vaccinated and boosted. The research also shows that these unvaccinated patients face higher risks of hospitalization and ICU admission if infected with the virus.
A large-scale study found a link between SARS-CoV-2 mRNA vaccinations and an increased risk of myocarditis, particularly among younger individuals. The study, published in JAMA Cardiology, analyzed data from Denmark, Finland, Norway, and Sweden.
A new international study confirms the low risk of myopericarditis following COVID-19 vaccination, with a rate of 18 cases per million doses. The study found no statistically significant difference between the incidence of myopericarditis after COVID-19 vaccination and other vaccinations.
A study of almost 57,000 hospitalizations with COVID-19 found acute myocarditis occurred in about two out of every 1,000 people. This rare condition is associated with more severe illness and complications, especially among those with pneumonia. The analysis suggests a need for intensive care unit admission in up to 70.5% of cases.
Researchers developed innovative smart sensors to test new vaccines, revealing significant discrepancies between subjective self-reports and objective measurements. The study found that side effects escalate over the first 48 hours and then stabilize, with parameters returning to pre-vaccination levels.
Researchers developed a novel approach to diagnose, monitor, and predict the course of myocarditis using CMR parameters and AI. The goal is to provide personalized counseling for athletes and optimize treatment options.
A new study published in Radiology found that COVID-19 vaccine-associated myocarditis tends to be less severe and resolve quickly compared to other causes of myocarditis. The study analyzed data from 92 patients with cardiac MRI abnormalities and found that those with vaccine-associated myocarditis had less functional impairment and le...
Scientists at UC Riverside and UCLA have engineered nanoparticles to serve as 'molecular traps' that bind to SARS-CoV-2, preventing it from attacking macrophages and inducing inflammation. The findings suggest potential therapeutic strategies for treating COVID-19-associated diseases.
This study examined reports of myocarditis after mRNA-based COVID-19 vaccination, finding a higher risk among younger males. The researchers estimated the risk based on age, sex, and vaccine type, providing valuable insights into the potential side effects of these vaccines.
A study of nearly 5 million Danish residents finds mRNA vaccines associated with a low risk of myocarditis or myopericarditis after COVID-19 vaccination, particularly for Moderna and Pfizer-BioNTech. Absolute numbers are low, even in younger age groups.
A study by Boston Children's Hospital found that COVID-19 vaccination-related myocarditis is usually mild and has a fast clinical recovery rate in adolescents and young adults. However, long-term monitoring of heart health is recommended due to potential cardiac complications.
Researchers found that most cases of suspected COVID-19 vaccine-related myocarditis in people younger than 21 are mild and resolve quickly. The study suggests that the benefits of COVID-19 vaccination far exceed the rare risks of adverse events, including myocarditis.
A large study of collegiate athletes reveals persistent COVID-19 symptoms are rare, but exertional chest pain warrants further clinical evaluation. The study used the Outcomes Registry for Cardiac Conditions in Athletes and found low prevalence of exertional symptoms upon return to exercise.
A new clinical syndrome of ICI-myocarditis has been identified, characterized by highly arrhythmogenic features. The study establishes specific electrocardiographic features to diagnose and prognosticate the syndrome, highlighting the need for further research on prediction and monitoring strategies.
A recent study published in the American Journal of Roentgenology found a link between COVID-19 mRNA vaccination and myocarditis in adolescent males. Cardiac MRI was used to assess suspected myocarditis post-vaccination, with late gadolinium enhancement persisting in two patients undergoing repeat MRI.
A population-based study of 2.4 million people found rare cases of acute myocarditis after COVID-19 mRNA vaccination in young men. The study suggests that the signal of increased myocarditis warrants further investigation into the relationship between COVID-19 vaccines and cardiac complications.
A comprehensive study of 6.2 million patients found no serious health effects linked to mRNA COVID-19 vaccines, with some early findings previously reported at CDC meetings. The Vaccine Safety Datalink's COVID-19 rapid cycle analysis will continue tracking vaccinated patients for at least 2 years.